DOCSLIB.ORG

Topical 0 3% Ciprofloxacin, Norfloxacin, And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Topical 0 3% Ciprofloxacin, Norfloxacin, And 606 British Journal of Ophthalmology 1995; 79: 606-609 Topical 0 3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new Br J Ophthalmol: first published as 10.1136/bjo.79.6.606 on 1 June 1995. Downloaded from method for comparative evaluation of ocular drug penetration Jeremy P Diamond, Les White, John P Leeming, H Bing Hoh, David L Easty Abstract dry eye, contact lens use, trauma, or the Aims-This study was designed to assess presence of a persistent comeal suture. the relative corneal penetration of topical Subsequent long term visual loss occurs as a drops of three antibiotics and to relate consequence of comeal scarring affecting the those levels to minimum inhibitory con- visual axis. The extent of scarring may be centrations for organisms associated with limited if the infection is identified early and bacterial keratitis. treated adequately. Optimal management Methods-Four drops of each of requires an attempt to isolate the causative ciprofloxacin, norfloxacin, and ofloxacin organism in order to ensure appropriate anti- (0.30/o topical ophthalmic preparations) biotic treatment. However, the aetiological were given to 12 patients undergoing agent is rarely known in time to guide initial corneal transplantation. After the recipi- antibiotic treatment and frequently is never ent tissue was removed, corneal drug identified. Thus, successful treatment of a pre- penetration was measured using high per- sumed bacterial comeal abscess is often depen- formance liquid chromatography. dent on empirical selection of an effective Results-Intracorneal concentrations of broad spectrum antibiotic regimen. For many ofloxacin (geometric mean 0-81 mg kg-1) years the most widely accepted option has been were significantly higher than both the instillation of a combination of a a lactam ciprofloxacin (0-60 mg kg-1; p=0.048) and and an aminoglycoside, both in high concen- norfloxacin (0.54 mg kg-1; p=0.012). tration solutions requiring local formulation. Ciprofloxacin and norfloxacin concentra- The fluoroquinolones are broad spectrum University ofBristol, tions did not differ significantly (p=0*33). bactericidal agents with activity against many of Departnent of Ophthalmology, Conclusions-Review of the minimum the important comeal pathogens including http://bjo.bmj.com/ Bristol Eye Hospital, inhibitory concentrations of the fluoro- staphylococci, Neisseria gonorrhoea, Haemophilus Bristol BS2 2LX quinolones against ocular pathogens influenzae, Enterobacteriaceae, and Pseudo- J P Diamond H Bing Hoh reveals that ciprofloxacin is more potent monas aeruginosa.1 2 Three fluoroquinolone D L Easty than ofloxacin against many bacteria; antibiotics have been formulated as 03%/o topi- ofloxacin is in turn more potent than nor- cal ophthalmic drops: ciprofloxacin (Alcon), Public Health Laboratory, Bristol floxacin. These data favour the selection norfloxacin (Merck, Sharpe and Dohme), and Royal Infirmary, of ciprofloxacin and ofloxacin rather than ofloxacin (Allergan). While these antibiotics on September 24, 2021 by guest. Protected copyright. Upper Maudlin Street, norfloxacin for the empirical treatment of have similar spectra of activity, they are not Bristol BS2 8HW J corneal infection. The greater potency of equally potent against many organisms and vary P Leeming ciprofloxacin offsets the superior penetra- in their pharmacokinetic properties.3 The Antimicrobial tion of ofloxacin. There is a need for success of an antibiotic depends on its ability to Reference Laboratory, improved clinical trial data concerning penetrate the site of infection in concentrations Department of Microbiology, the use of fluoroquinolone eyedrops in effective against the causative bacteria. There- Southmead Hospital, ulcerative keratitis; some encouraging fore, this project was designed to assess the rela- Bristol BS1O 5NB data are available for ciprofloxacin but tive comeal penetration oftopical drops ofthese L White not (in humans) for norfloxacin or antibiotics and to relate those levels to mini- Correspondence to: ofloxacin. mum inhibitory concentrations for organisms John P Leeming, Public Health Laboratory, Bristol (BrJ Ophthalmol 1995; 79: 606-609) commonly associated with bacterial keratitis. Royal Infirmary, Upper Maudlin Street, Bristol BS2 8HW. Accepted for publication Bacterial keratitis may arise secondary to Materials and methods 14 February 1995 comeal epithelial breakdown associated with Twelve patients due to undergo routine pene- trating keratoplasty (with or without cataract extraction) under general anaesthesia at the Table 1 Six quinolone antibiotic administration regimens showing the sequence in which patients received single drops oftopical 0 3% ciprofloxacin, norfioxacin, and ofloxacin, Bristol Eye Hospital were enrolled. Exclusion every 20 minutesfor 1 hour criteria included the presence of a broken corneal epithelium, active comeal inflamma- Sequence Start (0 min) + 20 min + 40 min + 60 min tory disease, topical antibiotic use during 1 Al/Bl Nor/Cip/Oflo Oflo/Nor/Cip Cip/Oflo/Nor Nor/Cip/Oflo week before enrolment, or a history of renal A2/B2 Oflo/Nor/Cip Cip/Oflo/Nor Nor/Cip/Oflo Oflo/Nor/Cip A3/B3 Cip/Oflo/Nor Nor/Cip/Oflo Oflo/Nor/Cip Cip/Oflo/Nor disease. Patients were given an information A4/B4 Nor/Oflo/Cip Cip/Nor/Oflo Oflo/Cip/Nor Nor/Oflo/Cip sheet pertaining to the trial before giving their A5/B5 Cip/Nor/Oflo Oflo/Cip/Nor Nor/Oflo/Cip Cip/Nor/Oflo A6/B6 Oflo/Cip/Nor informed consent. The trial was approved by Nor/Oflo/Cip Cip/Nor/Oflo Oflo/Cip/Nor the local ethics committee. Topical 0 3% ciprofloxacin, norfloxacin, and ofloxacin in treatment ofbacterial keratitis 607 drops and surgery was commenced within 60 minutes after instillation of the last antibiotic 0 4 drop. The host corneal button was snap frozen Br J Ophthalmol: first published as 10.1136/bjo.79.6.606 on 1 June 1995. Downloaded from in liquid nitrogen and stored at -70°C awaiting corneal drug assay. Corneal antibiotic concentrations were assayed by high performance liquid chroma- tography (HPLC) using methods based on those of McDermott4 and Gau.5 Corneal buttons were weighed, cut into small pieces with a scalpel, and homogenised in 500 [±l of water in a ground glass Griffiths tube. The bulk of the first homogenate was removed and a second 500 ,ul ofwater was added. After further homogenisation the solutions were pooled. After brief centrifugation the clear supernatant was analysed by HPLC on Spherisorb 5 ODS II (4X300 mm) (HPLC Technology, Macclesfield) at 50°C with a mobile phase of Water (1 litre) plus phosphoric acid (1 -6 ml) adjusted to pH 3-0 with tetrabutylammonium 0, hydroxide and mixed with acetonitrile (50 ml). d)qt 0 Flow rate was 1 ml min-I and detection was a1) by fluorescence (excitation 310 nm, emission 467 a Perkin-Elmer LC 240 0. nm) using detec- U) a) tor. External calibration was performed with an a) aqueous solution containing ciprofloxacin IL) c (1.67 mg l-l), norfloxacin (173 mg l-1), and a) C) ofloxacin (1 67 mg 1-1). Twenty ,ul ofcalibrator a)Co solution were processed in the same manner as 0 the corneal samples. The drug concentration in each corneal sample was determined by taking C C the dilution factor of the calibrator as 20/1020 0 and the dilution factor of the tests as x/l000+x 00 where x is the weight of the corneal plug in mg. Preliminary experiments (data not shown) indicated >95% recovery of calibrator solution processed in the presence of drug free cornea. http://bjo.bmj.com/ Typical within assay reproducibility was plus or minus 16% or better. A brief literature review was conducted to identify the bacterial species most commonly 0 6 implicated in keratitis and their sensitivity to the o fluoroquinolones studied. Where possible data 0)0 were selected from publications in which the on September 24, 2021 by guest. Protected copyright. C c sensitivities of bacteria of interest to all three ._F-0) 0 antimicrobials were compared. For each fluoro- quinolone the mean intracorneal concentration was expressed as a proportion of the minimum Figure 1 High concentration required to inhibit the growth of performance liquid 90% of isolates of these species (MIC90). The chromatogram of fluoroquinolones. Elution resultant coefficients were used to assess the order ofloxacin, likely in vivo potency of each agent. norfloxacin, ciprofloxacin. Time (seconds) Topical preparations of 0 3% ciprofloxacin, Results norfloxacin, and ofloxacin were obtained from Nine (75 0%) female and three (25.0%) male their manufacturers and rebottled to ensure that subjects were recruited; the mean age was 49 the same drop volume was applied in each case. (range 7-87) years. Each drug administration Patients received four drops of each drug over a permutation listed in Table 1 was used for two 60 minute period as shown in Table 1. To avoid patients. The three fluoroquinolones were all bias resulting from their order of presentation baseline separated in the HPLC analysis. A the three antibiotics were administered in one of typical chromatogram is shown in Figure 1. six sequence permutations. The first patient The antibiotic concentrations found in the enrolled was randomly allocated an administra- corneal buttons are given in Table 2. The tion regimen and thereafter, patients received geometric mean values (and 95% confidence the next regimen in the sequence. Drops were limits) were: ciprofloxacin 0-60 mg kg-' administered at 2 minute intervals to avoid (038-0 95 mg kg-'), norfloxacin 0 54 mg kg-l overspill. Patients received concurrent surgical (0-36-0@95 mg kg-'), and ofloxacin 0-81 mg preparation with unpreserved miotic/mydriatic kg-l (0-51-1-28 mg kg-'). The difference 608 Diamond, White, Leeming, Bing Hoh, Easty Table 2 Corneal antibiotic concentration (mg/kg) for 12 variability; in this study the concentrations of patients receivingfour topical drops of 0 3% ciprofloxacin, norfloxacin, and ofloxacin over 60 minutes before each fluoroquinolone spanned a range of undergoing penetrating keratoplasty approximately tenfold (Table 2). In conse- Br J Ophthalmol: first published as 10.1136/bjo.79.6.606 on 1 June 1995.
Load more

Recommended publications
  • Intravenous Palonosetron Increases the Incidence of Qtc Prolongation During Sevoflurane General Anesthesia for Laparotomy
    Korean J Anesthesiol 2013 November 65(5): 397-402 Clinical Research Article http://dx.doi.org/10.4097/kjae.2013.65.5.397 Intravenous palonosetron increases the incidence of QTc prolongation during sevoflurane general anesthesia for laparotomy Jeong Jin Min, Yongjae Yoo, Tae Kyong Kim, and Jung-Man Lee Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea Background: Palonosetron is a recently introduced 5-hydroxytryptamine-3 (5-HT3) receptor antagonist useful for postoperative nausea and vomiting prophylaxis. However, 5-HT3 receptor antagonists increase the corrected QT (QTc) interval in patients who undergo general anesthesia. This retrospective study was performed to evaluate whether palono- setron would induce a QTc prolongation in patients undergoing general anesthesia with sevoflurane. Methods: We reviewed a database of 81 patients who underwent general anesthesia with sevoflurane. We divided the records into palonosetron (n = 41) and control (n = 40) groups according to the use of intraoperative palonosetron, and analyzed the electrocardiographic data before anesthesia and 30, 60, 90, and 120 min after skin incision. Changes in the QTc interval from baseline, mean blood pressure, heart rate, body temperature, and sevoflurane concentrations at each time point were compared between the two groups. Results: The QTc intervals at skin incision, and 30, 60, 90, and 120 min after the skin incision during general anesthesia were significantly longer than those at baseline in the two groups (P < 0.001). The changes in the QTc intervals were not different between the two groups (P = 0.41). However, six patients in the palonosetron group showed a QTc interval > 500 ms 30 min after skin incision, whereas no patient did in the control group (P = 0.01).
    [Show full text]
  • Antibacterial Effect of Sevoflurane and Isoflurane Ángel Martínez-Monsalve3 María Dolores Crespo- Sánchez1
    Original María Martínez-Serrano1 Manuel Gerónimo-Pardo2 Antibacterial effect of sevoflurane and isoflurane Ángel Martínez-Monsalve3 María Dolores Crespo- Sánchez1 1Servicio de Microbiología y Parasitología. Complejo Hospitalario Universitario de Albacete. 2Servicio de Anestesiología y Reanimación. Complejo Hospitalario Universitario de Albacete. 3Servicio de Cirugía Vascular. Complejo Hospitalario Universitario de Albacete. ABSTRACT property in vivo. This might then allow these agents to be con- sidered as rescue treatment against multidrug resistant patho- Introduction. Multidrug resistant bacteria are increasing gens, including a topical use in infected wounds. worldwide and therapeutic options are limited. Some anaes- Key words: Sevoflurane, Isoflurane, Anaesthetics, Inhala- thetics have shown antibacterial activity before. In this study, tion, Anti-Infective Agents. we have investigated the antibacterial effect of the halogen- ated anaesthetic agents sevoflurane and isoflurane against a range of resistant pathogens. Actividad antibacteriana de sevoflurano e Methods. Two experiments were conducted. In the first, isoflurano bacterial suspensions of both ATCC and resistant strains of Staphylococcus aureus, Escherichia coli and Pseudomonas RESUMEN aeruginosa were exposed to liquid sevoflurane and isoflurane during 15, 30 and 60 minutes. In the second experiment clinical Introducción. Las bacterias multirresistentes están au- resistant strains of E. coli, Klebsiella pneumoniae, Enterobac- mentando en todo el mundo y las opciones terapéuticas son ter cloacae, P. aeruginosa, Acinetobacter baumannii, S. aureus, limitadas. Algunos anestésicos han mostrado actividad an- and Enterococcus faecium were studied. Previously inoculated tibacteriana previamente. En este estudio hemos investigado agar plates were irrigated with the halogenated anaesthet- dicha actividad en los anestésicos halogenados sevoflurano e ic agents and these were left to evaporate before the plates isoflurano frente a un grupo de patógenos resistentes.
    [Show full text]
  • Antibacterial Activity and Mechanisms of Essential Oil from Citrus Medica L
    molecules Article Antibacterial Activity and Mechanisms of Essential Oil from Citrus medica L. var. sarcodactylis Ze-Hua Li 1,2, Ming Cai 2,*, Yuan-Shuai Liu 3, Pei-Long Sun 2,* and Shao-Lei Luo 2 1 College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou 310014, China; [email protected] 2 Department of Food Science and Technology, Zhejiang University of Technology, Hangzhou 310014, China; [email protected] 3 Department of Chemical and Biological Engineering, Hong Kong University of Science and Technology, Hong Kong; [email protected] * Correspondence: [email protected] (P.-L.S.); [email protected] (M.C.); Tel.: +86-0571-88320388 (P.-L.S.); +86-0571-88320345 (M.C.) Academic Editor: Francesca Mancianti Received: 29 March 2019; Accepted: 18 April 2019; Published: 22 April 2019 Abstract: In this work, antibacterial activity of finger citron essential oil (FCEO, Citrus medica L. var. sarcodactylis) and its mechanism against food-borne bacteria were evaluated. A total of 28 components in the oil were identified by gas chromatography-mass spectrometry, in which limonene (45.36%), γ-terpinene (21.23%), and dodecanoic acid (7.52%) were three main components. For in vitro antibacterial tests, FCEO exhibited moderately antibacterial activity against common food-borne bacteria: Escherichia coli, Staphylococcus aureus, Bacillus subtilis and Micrococcus luteus. It showed a better bactericidal effect on Gram-positive bacteria than Gram-negative. Mechanisms of the antibacterial action were investigated by observing changes of bacteria morphology according to scanning electron microscopy, time-kill analysis, and permeability of cell and membrane integrity. Morphology of tested bacteria was changed and damaged more seriously with increased concentration and exposure time of FCEO.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL Et Al
    US 20140296.191A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL et al. (43) Pub. Date: Oct. 2, 2014 (54) COMPOSITIONS OF PHARMACEUTICAL (52) U.S. Cl. ACTIVES CONTAINING DETHYLENE CPC ............... A61K 47/10 (2013.01); A61 K9/0019 GLYCOL MONOETHYLETHER OR OTHER (2013.01); A61 K9/0048 (2013.01); A61 K ALKYL DERVATIVES 45/06 (2013.01) USPC ........... 514/167: 514/177; 514/178: 514/450; (71) Applicant: THEMIS MEDICARE LIMITED, 514/334: 514/226.5: 514/449; 514/338; Mumbai (IN) 514/256; 514/570; 514/179; 514/174: 514/533; (72) Inventors: Dinesh Shantilal PATEL, Mumbai (IN); 514/629; 514/619 Sachin Dinesh PATEL, Mumbai (IN); Shashikant Prabhudas KURANI, Mumbai (IN); Madhavlal Govindlal (57) ABSTRACT PATEL, Mumbai (IN) (73) Assignee: THEMIS MEDICARE LIMITED, The present invention relates to pharmaceutical compositions Mumbai (IN) of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl (21) Appl. No.: 14/242,973 ether or other alkyl derivatives thereofas a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene (22) Filed: Apr. 2, 2014 glycol monoethyl ether or other alkyl derivatives thereofas a primary vehicle or as a solvent system in preparation of Such (30) Foreign Application Priority Data pharmaceutical compositions. The pharmaceutical composi Apr. 2, 2013 (IN) ......................... 1287/MUMA2013 tions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formu Publication Classification lations containing such pharmaceutical actives and are Suit able for use as injectables for intravenous and intramuscular (51) Int. Cl. administration, as well as for use as a preformed solution/ A647/ (2006.01) liquid for filling in and preparation of capsules, tablets, nasal A6 IK 45/06 (2006.01) sprays, gargles, dermal applications, gels, topicals, liquid oral A6 IK9/00 (2006.01) dosage forms and other dosage forms.
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Trend Analysis of Antibiotics Consumption Using WHO Aware Classification in Tertiary Care Hospital
    International Journal of Basic & Clinical Pharmacology Bhardwaj A et al. Int J Basic Clin Pharmacol. 2020 Nov;9(11):1675-1680 http:// www.ijbcp.com pISSN 2319-2003 | eISSN 2279-0780 DOI: https://dx.doi.org/10.18203/2319-2003.ijbcp20204493 Original Research Article Trend analysis of antibiotics consumption using WHO AWaRe classification in tertiary care hospital Ankit Bhardwaj*, Kaveri Kapoor, Vivek Singh Saraswathi institute of Medical Sciences, Pilakhuwa, Hapur, Uttar Pradesh, India Received: 21 August 2020 Accepted: 21 September 2020 *Correspondence: Dr. Ankit Bhardwaj, Email: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: Aim of the study was to assess trend in antibiotics consumption pattern from 2016 to 2019 using AWaRe classification, ATC and Defined daily dose methodology (DDD) in a tertiary care hospital. Antibiotics are crucial for treating infectious diseases and have significantly improved the prognosis of patients with infectious diseases, reducing morbidity and mortality. The aim of the study is to classify the antibiotic based on WHO AWaRe classification and compare their four-year consumption trends. The study was conducted at a tertiary care center, Pilakhuwa, Hapur. Antibiotic procurement data for a period of 4 years (2016-2019) was collected from the Central medical store. Methods: This is a retrospective time series analysis of systemic antibiotics with no intervention at patient level. Antibiotic procurement was taken as proxy for consumption assuming that same has been used.
    [Show full text]
  • 2016 Medicines in Development for Rare Diseases a LIST of ORPHAN DRUGS in the PIPELINE
    2016 Medicines in Development for Rare Diseases A LIST OF ORPHAN DRUGS IN THE PIPELINE Autoimmune Diseases Product Name Sponsor Official FDA Designation* Development Status Actemra® Genentech treatment of systemic sclerosis Phase III tocilizumab South San Francisco, CA www.gene.com Adempas® Bayer HealthCare Pharmaceuticals treatment of systemic sclerosis Phase II riociguat Whippany, NJ www.pharma.bayer.com ARA 290 Araim Pharmaceuticals treatment of neuropathic pain in patients Phase II Tarrytown, NY with sarcoidosis www.ariampharma.com ARG201 arGentis Pharmaceuticals treatment of diffuse systemic sclerosis Phase II (type 1 native bovine skin Collierville, TN www.argentisrx.com collagen) BYM338 Novartis Pharmaceuticals treatment of inclusion body myositis Phase III (bimagrumab) East Hanover, NJ www.novartis.com CCX168 ChemoCentryx treatment of anti-neutrophil cytoplasmic Phase II (5a receptor antagonist) Mountain View, CA auto-antibodies associated vasculitides www.chemocentryx.com (granulomatosis with polyangitis or Wegener's granulomatosis), microscopic polyangitis, and Churg-Strauss syndrome * This designation is issued by the FDA's Office of Orphan Products Development while the drug is still in development. The designation makes the sponsor of the drug eligible for entitlements under the Orphan Drug Act of 1983. The entitlements include seven years of marketing exclusivity following FDA approval of the drug for the designated use. Medicines in Development: Rare Diseases | 2016 1 Autoimmune Diseases Product Name Sponsor Official FDA
    [Show full text]
  • Paincomp® Thresholds V04.14.2021 Copyright © 2020 Aegis Sciences
    PainComp® Thresholds V04.14.2021 Tests and thresholds employed vary depending on ordered profile Urine Analyte Initial Confirm Units Test Alprazolam (Xanax) 200 50 ng/mL Amitriptyline 10 ng/mL Amobarbital (Amytal) 200 200 ng/mL Amphetamine (Adzenys ER , Adderall XR) 500 250 ng/mL Aripiprazole (Abilify) 10 ng/mL Armodafinil (Nuvigil)/Modafinil (Provigil) 100 ng/mL Asenapine (Saphris) 10 ng/mL Atomoxetine (Strattera) 10 ng/mL Baclofen 500 ng/mL Benzodiazepines (Chlordiazepoxide, Clorazepate, 200 50 ng/mL Diazepam, Oxazepam, Temazepam) Brexpiprazole (Rexulti) 10 ng/mL Buprenorphine/Sublingual (Belbuca) 1 ng/mL Buprenorphine/Transdermal patch (Butrans) 1 ng/mL Bupropion (Aplenzin, Forfivo XL) 50 ng/mL Buspirone 25 ng/mL Butalbital 200 200 ng/mL Butorphanol 1 ng/mL Caffeine 15 mcg/mL Carbamazepine 50 ng/mL Cariprazine (Vraylar) 20 ng/mL Carisoprodol (Soma)/Meprobamate 200 ng/mL Chlorpromazine 10 ng/mL Chlorzoxazone 500 ng/mL Citalopram (Celexa)/Escitalopram (Lexapro) 50 ng/mL Clomipramine (Anafranil) 10 ng/mL Clonazepam (Klonopin) 200 50 ng/mL Clonidine (Kapvay) 50 ng/mL Clozapine (Clozaril, Fazaclo) 50 ng/mL Cocaine 100 50 ng/mL Codeine 200 100 ng/mL Cotinine/Nicotine metabolite (Habitrol, Nicoderm CQ) 125 ng/mL Cyclobenzaprine (Amrix) 10 ng/mL Dantrolene (Dantrium) 50 ng/mL Designer Benzodiazepines Adinazolam 5 ng/mL Bromazolam 1 ng/mL Clonazolam 1 ng/mL Copyright © 2020 Aegis Sciences Corporation All Rights Reserved PainComp® Thresholds V04.14.2021 Deschloroetizolam 1 ng/mL Diclazepam 1 ng/mL Etizolam 1 ng/mL Flualprazolam 1 ng/mL Flubromazepam
    [Show full text]
  • Pharmacology-2/ Dr
    1 Pharmacology-2/ Dr. Y. Abusamra Pharmacology-2 Quinolones, trimethoprim & sulfonamides Dr. Yousef Abdel - Kareem Abusamra Faculty of Pharmacy Philadelphia University 2 3 LEARNING OUTCOMES After completing studying this chapter, the student should be able to: Classify the drugs into subgroups such as quinolones and sulfonamides. Recognize the bacterial spectrum of all these antibiotic and antibacterial groups. Summarize the most remarkable pharmacokinetic features of these drugs. Numerate the most important side effects associated with these agents. Select the antibiotic of choice to be used in certain infections, as associated with the patient status including comorbidity, the species of bacteria causing the infection and concurrently prescribed drugs. Reason some remarkable clinical considerations related to the use or contraindication or precaution of a certain drug. Illustrate the mechanism of action of each of these drugs. • Following synthesis of na lidixic a c id in the early 1960s, continued modification of the quinolone nucleus expanded the spectrum of activity, improved pharmacokinetics, and stabilized compounds against common mechanisms of resistance. • Overuse resulted in rising rates of resistance in gram-negative and gram-positive organisms, increased frequency of Clostridium difficile infections, and identification of numerous tough adverse effects. • Consequently, these agents have been relegated to second-line options for various indications. 4 Pharmacology-2/ Dr. Y. Abusamra Only will be mentioned here 5 Pharmacology-2/ Dr. Y. Abusamra Most bacterial species maintain two distinct type II topoisomerases that assist with deoxyribonucleic acid Topoisomerases: Supercoiling Unwinding (DNA) replication: . DNA gyrase {supercoiling} and . Topoisomerase IV {Unwinding}. Following cell wall entry through porin channels, fluoroquinolones bind to these enzymes and interfere with DNA ligation.
    [Show full text]
  • Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act
    Updated June 07, 2021 Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Three categories of bulk drug substances: • Category 1: Bulk Drug Substances Under Evaluation • Category 2: Bulk Drug Substances that Raise Significant Safety Risks • Category 3: Bulk Drug Substances Nominated Without Adequate Support Updates to Categories of Substances Nominated for the 503B Bulk Drug Substances List1 • Add the following entry to category 2 due to serious safety concerns of mutagenicity, cytotoxicity, and possible carcinogenicity when quinacrine hydrochloride is used for intrauterine administration for non- surgical female sterilization: 2,3 o Quinacrine Hydrochloride for intrauterine administration • Revision to category 1 for clarity: o Modify the entry for “Quinacrine Hydrochloride” to “Quinacrine Hydrochloride (except for intrauterine administration).” • Revision to category 1 to correct a substance name error: o Correct the error in the substance name “DHEA (dehydroepiandosterone)” to “DHEA (dehydroepiandrosterone).” 1 For the purposes of the substance names in the categories, hydrated forms of the substance are included in the scope of the substance name. 2 Quinacrine HCl was previously reviewed in 2016 as part of FDA’s consideration of this bulk drug substance for inclusion on the 503A Bulks List. As part of this review, the Division of Bone, Reproductive and Urologic Products (DBRUP), now the Division of Urology, Obstetrics and Gynecology (DUOG), evaluated the nomination of quinacrine for intrauterine administration for non-surgical female sterilization and recommended that quinacrine should not be included on the 503A Bulks List for this use. This recommendation was based on the lack of information on efficacy comparable to other available methods of female sterilization and serious safety concerns of mutagenicity, cytotoxicity and possible carcinogenicity in use of quinacrine for this indication and route of administration.
    [Show full text]
  • < INVENTED NAME > See Annex1 Film-Coated Tablet 2. Q
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT < INVENTED NAME > see annex1 film-coated tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 Film-coated tablet contains 400 mg norfloxacin. Excipient with known effects Each film-coated tablet contains 0.5 mg sunset yellow (E110) and 3.36 mg sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet Round, orange film-coated tablet, with an engraved line on one side. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications < INVENTED NAME > is indicated for the treatment of the following infections caused by norfloxacin-susceptible bacteria (see sections 4.2 and 5.1): Uncomplicated acute cystitis. In uncomplicated acute cystitis < INVENTED NAME > should be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the treatment of these infections. Urethritis including cases due to susceptible Neisseria gonorrhoeae Complicated urinary tract infections (except complicated pyelonephritis) Complicated acute cystitis Consideration should be given to official guidance on the appropriate use of antibacterial agents. 4.2 Posology and method of administration Posology The dosage depends on the susceptibility of the pathogens and severity of the disease, see recommended dosage in the table below. Susceptibility of the causative organism to the treatment should be tested (if possible), although therapy may be initiated before the results are available. In case of suspected failure of therapy, microbiological investigation for possible bacterial resistance should be undertaken.
    [Show full text]